Ph.D., Chief Business & Product Development Officer, Genomic Health

Over the last 25 years, Frederic Pla has built and launched global businesses in medical diagnostics and devices, life sciences, and healthcare information technology, consistently delivering high growth and profitability through a blend of product innovation, strategic acquisitions, and successful turnarounds. Before joining Genomic Health in 2014 as Chief Business & Product Development Officer, Frederic was the Vice President, Corporate Business Development, for Life Technologies, a $4 billion, 11,000 employee, San Diego-based global life sciences business, until its acquisition by Thermo Fisher in 2014. Frederic led many of the company’s internal and external growth initiatives, adding nearly $2.5 billion in yearly revenue through 30 acquisitions across areas such as diagnostics, food safety and animal health, bioinformatics and life sciences tools. Frederic joined Life Technologies in 2005 as Vice President and General Manager of the Diagnostics Business, responsible for product development and manufacturing facilities in the US, UK, and China. Under Frederic’s leadership, this global business provided physicians with a complete set of tools to aid in solid organ and bone marrow transplant diagnostics, sold worldwide through a dedicated global sales force and distributor network. Prior to joining Life Technologies, Fred held global managerial positions of increasing responsibilities at GE Healthcare, including General Manager for the Cardiology IT and Enterprise IT businesses, where Frederic contributed to the formation and growth of GE’s $2.4 billion Healthcare IT business; and Digital X-Ray Marketing, where he led the introduction of GE’s revolutionary digital X-Ray detector technology. Frederic started his career in R&D, first at the NASA Glenn Research Center in Cleveland, OH, and then at GE’s Global Research Center in Schenectady, NY. He is fluent in French, holds 23 U.S. patents, a Ph.D. in Acoustics from the Pennsylvania State University, a Master’s Degree from The University of Southampton, UK, and an Engineering Degree from the University of Technology of Compiegne, France.


Liquid Biopsies in the Management of Cancer

Liquid biopsies can be used to monitor tumor dynamics including recurrence or to profile individual genetic and genomic markers that are informative of treatment options. 
Together, these complementary approaches provide precision solutions to help manage disease along the patient cancer journey.  These also call for different development, analytical and clinical validation strategies, and demonstration of clinical utility.      

Web Analytics